Selby P J, Powles R L, Janeson B, Kay H E, Watson J G, Thornton R, Morgenstern G, Clink H M, McElwain T J, Prentice H G, Corringharn R, Ross M G, Hoffbrand A V, Brigden D
Lancet. 1979 Dec 15;2(8155):1267-70. doi: 10.1016/s0140-6736(79)92281-5.
Acyclovir is a new antiviral agent which is highly active against herpesviruses in vitro and in laboratory animals. Twenty-three cancer patients with cutaneous and/or systemic herpes zoster or herpes simplex infections were treated with parenteral acyclovir. All had received previous specific treatment for their malignant disease and ten had undergone bone-marrow transplantation. The drug seemed to arrest the progress of the infections and was most effective when given early. Although two patients showed transient increases in blood-urea, possibly the result of acyclovir, the drug was remarkably non-toxic in the doses used.
阿昔洛韦是一种新型抗病毒药,在体外及实验动物体内对疱疹病毒均具有高效活性。23例患有皮肤和/或全身性带状疱疹或单纯疱疹感染的癌症患者接受了阿昔洛韦注射治疗。所有患者此前均已接受针对其恶性疾病的特定治疗,其中10例接受了骨髓移植。该药物似乎能阻止感染进展,且早期给药时效果最佳。尽管有2例患者血尿素短暂升高,可能是阿昔洛韦所致,但在所使用的剂量下该药物毒性极低。